Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Today's Latest Price: $12.32 USD
Updated Jan 26 7:00pm
Add TEVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
TEVA Stock Summary
- Teva Pharmaceutical Industries Ltd's market capitalization of $13,590,047,294 is ahead of 85.42% of US-listed equities.
- Teva Pharmaceutical Industries Ltd's stock had its IPO on March 26, 1990, making it an older stock than 84.18% of US equities in our set.
- Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 14.72%, greater than the shareholder yield of 87.45% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Teva Pharmaceutical Industries Ltd are OC, IMO, ATO, CCL, and ASH.
- Visit TEVA's SEC page to see the company's official filings. To visit the company's web site, go to www.tevapharm.com.
TEVA Stock Price Chart Interactive Chart >
TEVA Price/Volume Stats
| Current price | $12.32 | 52-week high | $13.76 |
| Prev. close | $12.40 | 52-week low | $6.25 |
| Day low | $12.15 | Volume | 5,263,000 |
| Day high | $12.48 | Avg. volume | 10,929,600 |
| 50-day MA | $10.45 | Dividend yield | N/A |
| 200-day MA | $10.62 | Market Cap | 13.46B |
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $12.32 | $0.45 | -96% |
We started the process of determining a valid price forecast for Teva Pharmaceutical Industries Ltd with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 7th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Teva Pharmaceutical Industries Ltd, consider:
- Interest coverage, a measure of earnings relative to interest payments, is -4.72; that's higher than just 13.34% of US stocks in the Healthcare sector that have positive free cash flow.
- The company's compound free cash flow growth rate over the past 4.74 years comes in at -0.29%; that's greater than only 5.54% of US stocks we're applying DCF forecasting to.
- 34% of the company's capital comes from equity, which is greater than only 10.22% of stocks in our cash flow based forecasting set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -96% |
| 1% | -96% |
| 2% | -96% |
| 3% | -96% |
| 4% | -96% |
| 5% | -96% |
NVST, SXTC, INFU, LUMO, and OSMT can be thought of as valuation peers to TEVA, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...